Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Alexion Pharmaceuticals, Inc. ALXN breached their fiduciary duties to shareholders. Alexion, a biopharmaceutical company, develops and commercializes life-transforming therapeutic products.

View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/alexion-pharmaceuticals-inc

Alexion Under Investigation By the U.S. Health Inspector General

Alexion is under investigation by the U.S. Department of Health and Human Services' Office of Inspector General related to a probe by the U.S. Attorney's Office for the District of Massachusetts and the Department of Justice concerning the company's support for charities that aid Medicare patients. A Bloomberg investigation in May found a widespread culture of aggressive sales at Alexion aimed at seeking new potential customers and keeping patients on Alexion's main drug, Soliris. Alexion also disclosed that it is under investigation by the U.S. Securities and Exchange Commission and Department of Justice for issues related to the Foreign Corrupt Practices Act in Brazil.

Alexion Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170719006151/en/